<scp>DKK1</scp> drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with <scp>anti‐DKK1</scp> therapeutic <scp>DKN</scp> ‐01

Edward J. Jarman(Western General Hospital), Luke Boulter(Edinburgh Cancer Research), Stephanie MacMaster(Institute of Genetics and Cancer), David H. Wilson(University of Zimbabwe), Konstantinos Gournopanos(Institute of Genetics and Cancer), Michael H. Kagey, Panagiota Tsokkou(Medical University of Vienna), Marta Horcas‐Lopez(MRC Centre for Reproductive Health), Jeffrey W. Pollard(MRC Centre for Reproductive Health), Scott H. Waddell(Edinburgh Cancer Research), William Cambridge(Institute of Genetics and Cancer), Walter Newman(Ensemble Therapeutics (United States)), Minn E Ng(Institute of Genetics and Cancer), Kamila Irena Musialik(Institute of Genetics and Cancer), Daniel Soong(MRC Centre for Reproductive Health)
Liver International
August 4, 2022
Cited by 20


Related Papers